Rollins, Inc. Share Price Target ‘$46.74’, now 1.3% Upside Potential

DirectorsTalk Interviews

Rollins, Inc. which can be found using ticker (ROL) now have 9 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $52.00 and $37.00 calculating the mean target share price we have $46.74. (at the time of writing). Given that the stocks previous close was at $46.13 this now indicates there is a potential upside of 1.3%. The day 50 moving average is $45.42 and the 200 day MA is $41.58. The market capitalization for the company is 22.67B. The stock price for the company is currently is currently $46.79 USD

The potential market cap would be $22,971,187,903 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 51.99, revenue per share of $6.49 and a 15.94% return on assets.

Rollins, Inc. (Rollins) is an international services company. The Company provides pest and wildlife control services and protection against termite damage, rodents, and insects to both residential and commercial customers through its wholly owned subsidiaries and independent franchises located in approximately 70 countries, including United States, Canada, Australia, Europe, and Asia with international franchises in Canada, Central and South America, the Caribbean, Europe, the Middle East, Asia, Africa, and Australia. Rollins operates under three business lines, namely Residential, which includes pest control services protecting residential properties from common pests, including rodents, insects and wildlife; Commercial, which consist of workplace pest control solutions for customers across diverse end markets such as healthcare, foodservice, logistics, and Termite, which consist of traditional and baiting termite protection services and ancillary services for customers.

Share on:

Latest Company News

Genflow Biosciences reports early findings from SIRT6 gene therapy study

Genflow Biosciences reports early findings from its SIRT6 gene therapy study in older dogs, with further monitoring planned over...

Ilika CEO to discuss battery gigafactory development at Barcelona industry forum

Ilika CEO Graeme Purdy is set to speak at the December 2026 Barcelona battery gigafactory forum, bringing the company's...

Investors demand clear returns as AI spending comes under scrutiny

Investors are demanding clearer returns from AI spending as technology shares face pressure, with corporate earnings, data centre investment...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

itim Group targets retail AI market with new platform launch

ITIM Group is targeting the retail AI market with itimAIQ, a new platform designed to automate operations, improve efficiency...

Drax sets date for 2026 Capital Markets Day and trading update

Drax Group will host its Capital Markets Day on 23 November 2026, providing investors and analysts with a management...

    Search